Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors

BACKGROUND: Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved in 2014 to improve progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally ad...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Gastrointest Oncol
Autores principales: Saif, Muhammad Wasif, Parikh, Rohan, Ray, David, Kaye, James A., Kurosky, Samantha K., Thomas, Katharine, Ramirez, Robert A., Halfdanarson, Thorvardur R., Beveridge, Thomas J. R., Mirakhur, Beloo, Nagar, Saurabh P., Soares, Heloisa P.
Formato: Artigo
Lenguaje:Inglês
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657323/
https://ncbi.nlm.nih.gov/pubmed/31392048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.03.11
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares